胰高血糖素样肽-1 受体/葡萄糖依赖性胰岛素释放肽受体/胰高血糖素受体三激动剂治疗肥胖症和 2 型糖尿病的潜力。
Potential of a glucagon-like peptide-1 receptor/glucose-dependent insulinotropic polypeptide receptor/glucagon receptor triagonist for the treatment of obesity and type 2 diabetes.
机构信息
Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Center for Metabolic Regulation of Healthy Aging, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
出版信息
J Diabetes Investig. 2022 Dec;13(12):1958-1960. doi: 10.1111/jdi.13896. Epub 2022 Aug 30.
Abstract
Triagonists of GLP-1R/ GIPR /GCGR, including SAR441255, bind to each receptor and induce specific effects through each receptor signaling pathway, thus result in weight loss and glycemic control in obese T2D animal models.
摘要
GLP-1R/GIPR/GCGR 的三激动剂，包括 SAR441255，与每个受体结合，并通过每个受体信号通路诱导特定的效应，从而导致肥胖 2 型糖尿病动物模型的体重减轻和血糖控制。
Zotero 插件